Vol. 24/No. 1

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.

Data presented during the 2022 ASH Annual Meeting and Exposition showcased practice-changing updates from several studies across hematologic malignancies. Experts across hematologic cancers were on hand to discuss long-term readouts, the introduction of novel regimens for several diseases, and the impact of new data and trends in care for patients.

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.

Leading experts in the field of liver cancer contextualized how recent data are influencing the treatment paradigm in hepatocellular carcinoma.

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

The biomarker claudin 18.2 has recently shown promise as an intriguing new target in the gastroesophageal junction adenocarcinoma space.